• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis

  • ID: 2368620
  • November 2012
  • Region: China
  • 70 pages
  • GlobalData

PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis


GlobalData has released its new Country report, “PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

The Chinese influenza READ MORE >

Note: Product cover images may vary from those shown


1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Influenza Vaccination Policy
4.2 China
4.2.1 Influenza Vaccination Recommendations and Policies
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 FluMist
5.3.2 Afluria
5.3.3 Vaxigrip/Mutagrip
5.3.4 Influvac
5.3.5 Agrippal
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Higher level of patient awareness
6.2.2 Increased efficacy in the elderly and young children (<2 years old)
6.2.3 Improved vaccine side-effect profiles
6.2.4 More efficient vaccine manufacturing process
6.2.5 More cost-effective vaccines
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Expanded breadth of protection against viral strains
6.4.2 Increased duration of protection
6.4.3 T-cell involvement
7 Pipeline Assessment
7.1 Overview
8 Market Outlook
8.1 China
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Vaccine Coverage
9.4.2 Vaccines Included
9.4.3 Key Launch Dates
9.4.4 Influenza Vaccine Tender System Assumptions
9.4.5 General Pricing Assumptions
9.4.6 Individual Vaccine Assumptions
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About Us
9.9 Contact Us
9.10 Disclaimer

1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Leading Influenza Vaccines, 2012
Table 5: Product Profile - FluMist
Table 6: FluMist SWOT Analysis, 2012
Table 7: Product Profile - Afluria
Table 8: Afluria SWOT Analysis, 2012
Table 9: Product Profile - Vaxigrip
Table 10: Laboratory-Confirmed Influenza Infection Rates in Vaccine or Placebo Recipients and their Household Contacts
Table 11: Vaxigrip SWOT Analysis, 2012
Table 12: Product Profile - Influvac
Table 13: Influvac SWOT Analysis, 2012
Table 14: Product Profile - Agrippal
Table 15: Agrippal SWOT Analysis, 2012
Table 16: Overall Unmet Needs - Current Level of Attainment
Table 17: Clinical Unmet Needs - Gap Analysis, 2012
Table 18: Sales Forecasts ($m) for Influenza Vaccines in China, 2012-2022
Table 19: Key Events Impacting Sales of Influenza Vaccines in China, 2012
Table 20: Influenza Vaccine Market - Drivers and Barriers, 2012
Table 21: Epidemiology and Market Forecast Chinese Influenza Vaccination Rates (%), 2012-2022
Table 22: Key Launch Dates
Table 23: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Influenza Virus Structure
Figure 2: Sales for Influenza Vaccine in China by Route of administration, 2012-2022

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Pfizer, Inc. Grünenthal GmbH GlaxoSmithKline PLC Abbott Laboratories Ltd. Roche Diagnostics Ltd. Novo Nordisk A/S